Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Research-grade cranberry

This article was originally published in The Tan Sheet

Executive Summary

McKesson's BioServices division has inked a five-year, $2.8 mil. contract with NCCAM to develop research-grade cranberry products for center-funded basic, clinical research on role of cranberry "in the prevention and treatment of urinary tract infections" and other applications, firm says Oct. 23. McKesson will subcontract with Ocean Spray, which will donate "research product and analytical research services." Test batches and prototypes are being developed now for a cranberry capsule, placebo capsule, standardized juice cocktail similar to firm's flagship beverage and placebo beverage that replicates cocktail flavor without cranberry. McKesson's responsibilities will include labeling, storage, distribution and delivery of products. Actual product for use in research expected in Fall 2003...

You may also be interested in...



Cranberry Research Supported With $2.6 Mil. In NIH Funding

NIH plans to commit up to $2.6 mil. in fiscal year 2004 for Phase I and II trials on cranberry and its constituents' role in the treatment and prevention of urinary tract infections and other conditions

The Golden Winged Warbler And Creating Pharma Supply Chain Immunity

Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.

Bumpy Japan Zolgensma Review Holds Lessons For Applicants

Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.

Topics

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel